{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:08:54Z","timestamp":1780078134279,"version":"3.54.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disorder characterised by recurrent and often life-threatening infections and hyperinflammation. It is caused by defects of the phagocytic NADPH oxidase, a multicomponent enzyme system responsible for effective pathogen killing. A phase I\/II clinical trial of lentiviral gene therapy is underway for the most common form of CGD, X-linked, caused by mutations in the gp91<jats:sup>phox<\/jats:sup>subunit of the NADPH oxidase. We propose to use a similar strategy to tackle p47<jats:sup>phox<\/jats:sup>-deficient CGD, caused by mutations in<jats:italic>NCF1<\/jats:italic>, which encodes the p47<jats:sup>phox<\/jats:sup>cytosolic component of the enzymatic complex. We generated a pCCLCHIM-p47<jats:sup>phox<\/jats:sup>lentiviral vector, containing the chimeric<jats:italic>Cathepsin G<\/jats:italic>\/<jats:italic>FES<\/jats:italic>myeloid promoter and a codon-optimised version of the human<jats:italic>NCF1<\/jats:italic>cDNA. Here we show that transduction with the pCCLCHIM-p47<jats:sup>phox<\/jats:sup>vector efficiently restores p47<jats:sup>phox<\/jats:sup>expression and biochemical NADPH oxidase function in p47<jats:sup>phox<\/jats:sup>-deficient human and murine cells. We also tested the ability of our gene therapy approach to control infection by challenging p47<jats:sup>phox<\/jats:sup>-null mice with<jats:italic>Salmonella<\/jats:italic>Typhimurium, a leading cause of sepsis in CGD patients, and found that mice reconstituted with lentivirus-transduced hematopoietic stem cells had a reduced bacterial load compared with untreated mice. Overall, our results potentially support the clinical development of a gene therapy approach using the pCCLCHIM-p47<jats:sup>phox<\/jats:sup>vector.<\/jats:p>","DOI":"10.1038\/s41434-020-0164-6","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T11:06:19Z","timestamp":1591959979000},"page":"459-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Lentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice"],"prefix":"10.1038","volume":"27","author":[{"given":"Andrea","family":"Schejtman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walmir Cutrim","family":"Arag\u00e3o-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zinicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Weisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan O.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2626-5037","authenticated-orcid":false,"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert B.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Condino-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-1984","authenticated-orcid":false,"given":"Giorgia","family":"Santilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"164_CR1","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1093\/jpids\/piy008","volume":"7","author":"NL Rider","year":"2018","unstructured":"Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018;7:S2\u20135.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"164_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.jaci.2018.09.019","volume":"143","author":"DC Thomas","year":"2019","unstructured":"Thomas DC, Charbonnier LM, Schejtman A, Aldhekri H, Coomber EL, Dufficy ER, et al. EROS\/CYBC1 mutations: decreased NADPH oxidase function and chronic granulomatous disease. J Allergy Clin Immunol. 2019;143:782\u2013785.e1.","journal-title":"J Allergy Clin Immunol"},{"key":"164_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06964-x","volume":"9","author":"GA Arnadottir","year":"2018","unstructured":"Arnadottir GA, Norddahl GL, Gudmundsdottir S, Agustsdottir AB, Sigurdsson S, Jensson BO, et al. A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease. Nat Commun. 2018;9:4447.","journal-title":"Nat Commun"},{"key":"164_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/9780470035399.ch8","volume":"279","author":"AW Segal","year":"2006","unstructured":"Segal AW. How superoxide production by neutrophil leukocytes kills microbes. Novartis Found Symp. 2006;279:92\u20138. discussion 98-100, 216-109","journal-title":"Novartis Found Symp"},{"key":"164_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1083\/jcb.200606027","volume":"176","author":"TA Fuchs","year":"2007","unstructured":"Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231\u201341.","journal-title":"J Cell Biol"},{"key":"164_CR6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.bbmt.2018.03.029","volume":"24","author":"AD Yanir","year":"2018","unstructured":"Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, et al. High incidence of autoimmune disease after hematopoietic stem cell transplantation for chronic granulomatous disease. Biol Blood Marrow Transplant. 2018;24:1643\u201350.","journal-title":"Biol Blood Marrow Transplant"},{"key":"164_CR7","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/jpids\/piy015","volume":"7","author":"JA Connelly","year":"2018","unstructured":"Connelly JA, Marsh R, Parikh S, Talano JA. Allogeneic hematopoietic cell transplantation for chronic granulomatous disease: controversies and state of the art. J Pediatric Infect Dis Soc. 2018;7:S31\u20139.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"164_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nm1393","volume":"12","author":"MG Ott","year":"2006","unstructured":"Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12:401\u20139.","journal-title":"Nat Med"},{"key":"164_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nm.2088","volume":"16","author":"S Stein","year":"2010","unstructured":"Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010;16:198\u2013204.","journal-title":"Nat Med"},{"key":"164_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/mt.2010.232","volume":"19","author":"M Grez","year":"2011","unstructured":"Grez M, Reichenbach J, Schwable J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther. 2011;19:28\u201335.","journal-title":"Mol Ther"},{"key":"164_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","volume":"26","author":"D Kohn","year":"2020","unstructured":"Kohn D, Booth C, Kang EM, Pai SY, Shaw KL, Santilli G, et al. Lentiviral vector gene therapy for X-linked chronic granulomatous disease. Nat Med. 2020;26:200\u20136.","journal-title":"Nat Med"},{"key":"164_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/mt.2010.226","volume":"19","author":"G Santilli","year":"2011","unstructured":"Santilli G, Almarza E, Brendel C, Choi U, Beilin C, Blundell MP, et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther. 2011;19:122\u201332.","journal-title":"Mol Ther"},{"key":"164_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaci.2013.05.039","volume":"132","author":"MY Koker","year":"2013","unstructured":"Koker MY, Camcioglu Y, van Leeuwen K, Kilic SS, Barlan I, Yilmaz M, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132:1156\u201363.e5.","journal-title":"J Allergy Clin Immunol"},{"key":"164_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s10875-011-9567-x","volume":"31","author":"F Fattahi","year":"2011","unstructured":"Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M, Fazlollahi MR, Mansouri SD, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31:792\u2013801.","journal-title":"J Clin Immunol"},{"key":"164_CR15","doi-asserted-by":"publisher","first-page":"e12767","DOI":"10.1111\/sji.12767","volume":"90","author":"S Tajik","year":"2019","unstructured":"Tajik S, Badalzadeh M, Fazlollahi MR, Houshmand M, Bazargan N, Movahedi M, et al. Genetic and molecular findings of 38 Iranian patients with chronic granulomatous disease caused by p47-phox defect. Scand J Immunol. 2019;90:e12767.","journal-title":"Scand J Immunol"},{"key":"164_CR16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.V97.1.305","volume":"97","author":"D Noack","year":"2001","unstructured":"Noack D, Rae J, Cross AR, Ellis BA, Newburger PE, Curnutte JT, et al. Autosomal recessive chronic granulomatous disease caused by defects in NCF-1, the gene encoding the phagocyte p47-phox: mutations not arising in the NCF-1 pseudogenes. Blood. 2001;97:305\u201311.","journal-title":"Blood"},{"key":"164_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/bloodadvances.2018023184","volume":"3","author":"DB Kuhns","year":"2019","unstructured":"Kuhns DB, Hsu AP, Sun D, Lau K, Fink D, Griffith P, et al. NCF1 (p47(phox))-deficient chronic granulomatous disease: comprehensive genetic and flow cytometric analysis. Blood Adv. 2019;3:136\u201347.","journal-title":"Blood Adv"},{"key":"164_CR18","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/cid\/ciu1154","volume":"60","author":"BE Marciano","year":"2015","unstructured":"Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60:1176\u201383.","journal-title":"Clin Infect Dis"},{"key":"164_CR19","doi-asserted-by":"publisher","first-page":"e5234","DOI":"10.1371\/journal.pone.0005234","volume":"4","author":"JM van den Berg","year":"2009","unstructured":"van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS ONE. 2009;4:e5234.","journal-title":"PLoS ONE"},{"key":"164_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/humc.2017.245","volume":"29","author":"C Brendel","year":"2018","unstructured":"Brendel C, Rothe M, Santilli G, Charrier S, Stein S, Kunkel H, et al. Non-clinical efficacy and safety studies on G1XCGD, a lentiviral vector for ex vivo gene therapy of X-linked chronic granulomatous disease. Hum Gene Ther Clin Dev. 2018;29:69\u201379.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"164_CR21","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/mt.2014.87","volume":"22","author":"M Chiriaco","year":"2014","unstructured":"Chiriaco M, Farinelli G, Capo V, Zonari E, Scaramuzza S, Di Matteo G, et al. Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. Mol Ther. 2014;22:1472\u201383.","journal-title":"Mol Ther"},{"key":"164_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/sj.gt.3302753","volume":"13","author":"C Goujon","year":"2006","unstructured":"Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther. 2006;13:991\u20134.","journal-title":"Gene Ther"},{"key":"164_CR23","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1089\/hum.2016.016","volume":"27","author":"D Leon-Rico","year":"2016","unstructured":"Leon-Rico D, Aldea M, Sanchez-Baltasar R, Mesa-Nunez C, Record J, Burns SO, et al. Lentiviral vector-mediated correction of a mouse model of leukocyte adhesion deficiency type I. Hum Gene Ther. 2016;27:668\u201378.","journal-title":"Hum Gene Ther"},{"key":"164_CR24","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature10195","volume":"474","author":"K Hrecka","year":"2011","unstructured":"Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474:658\u201361.","journal-title":"Nature"},{"key":"164_CR25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/hgtb.2012.157","volume":"24","author":"C Brendel","year":"2013","unstructured":"Brendel C, Hanseler W, Wohlgensinger V, Bianchi M, Tokmak S, Chen-Wichmann L, et al. Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy. Hum Gene Ther Methods. 2013;24:151\u20139.","journal-title":"Hum Gene Ther Methods"},{"key":"164_CR26","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/jpids\/piy011","volume":"7","author":"MD Keller","year":"2018","unstructured":"Keller MD, Notarangelo LD, Malech HL. Future of care for patients with chronic granulomatous disease: gene therapy and targeted molecular medicine. J Pediatric Infect Dis Soc. 2018;7:S40\u20134.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"164_CR27","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1084\/jem.20161382","volume":"214","author":"DC Thomas","year":"2017","unstructured":"Thomas DC, Clare S, Sowerby JM, Pardo M, Juss JK, Goulding DA, et al. Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity. J Exp Med. 2017;214:1111\u201328.","journal-title":"J Exp Med"},{"key":"164_CR28","doi-asserted-by":"publisher","first-page":"e77204","DOI":"10.1371\/journal.pone.0077204","volume":"8","author":"B Felmy","year":"2013","unstructured":"Felmy B, Songhet P, Slack EM, Muller AJ, Kremer M, Van Maele L, et al. NADPH oxidase deficient mice develop colitis and bacteremia upon infection with normally avirulent, TTSS-1- and TTSS-2-deficient Salmonella Typhimurium. PLoS ONE. 2013;8:e77204.","journal-title":"PLoS ONE"},{"key":"164_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","volume":"141","author":"BE Marciano","year":"2018","unstructured":"Marciano BE, Zerbe CS, Falcone EL, Ding L, DeRavin SS, Daub J, et al. X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability. J Allergy Clin Immunol. 2018;141:365\u201371.","journal-title":"J Allergy Clin Immunol"},{"key":"164_CR30","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","volume":"363","author":"DB Kuhns","year":"2010","unstructured":"Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363:2600\u201310.","journal-title":"N Engl J Med"},{"key":"164_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/mt.2014.195","volume":"23","author":"RK Merling","year":"2015","unstructured":"Merling RK, Sweeney CL, Chu J, Bodansky A, Choi U, Priel DL, et al. An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol Ther. 2015;23:147\u201357.","journal-title":"Mol Ther"},{"key":"164_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1182\/bloodadvances.2016001214","volume":"1","author":"RK Merling","year":"2017","unstructured":"Merling RK, Kuhns DB, Sweeney CL, Wu X, Burkett S, Chu J, et al. Gene-edited pseudogene resurrection corrects p47(phox)-deficient chronic granulomatous disease. Blood Adv. 2017;1:270\u20138.","journal-title":"Blood Adv"},{"key":"164_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaci.2015.11.028","volume":"138","author":"M Weisser","year":"2016","unstructured":"Weisser M, Demel UM, Stein S, Chen-Wichmann L, Touzot F, Santilli G, et al. Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions. J Allergy Clin Immunol. 2016;138:219\u201328.e9.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0164-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41434-020-0164-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:38:31Z","timestamp":1696235911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-0164-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-0164-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AJT is on the Scientific Advisory Board of Orchard Therapeutics and Rocket Pharmaceuticals. HBG is the Chief Scientific Officer for Orchard Therapeutics. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}